Date | Price Target | Rating | Analyst |
---|---|---|---|
8/19/2024 | Outperform → Strong Buy | Raymond James | |
8/16/2024 | $27.00 | Outperform | Raymond James |
6/25/2024 | Perform | Oppenheimer | |
1/5/2024 | $18.00 → $28.00 | Buy | Needham |
9/19/2022 | $3.00 | Underperform | Wedbush |
9/1/2022 | $3.00 | Neutral → Underperform | Wedbush |
7/22/2022 | $15.00 | Buy | Ladenburg Thalmann |
5/31/2022 | $14.00 | Buy | BTIG Research |
MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of common stock in the public offering at a price of $8.90 per share. In addition, Liquidia entered into a common stock purchase agreement with funds managed by Caligan Partners LP for the sa
MORRISVILLE, N.C., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the following investor conferences this September: 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, from 11:00 – 11:35 a.m. ET2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, from 1:30 – 1:50 p.m. ET Access to the webcasts will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-presentations. An ar
MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed litigation in the U.S. District Court of the District of Columbia (Case No. 1:24-cv-02428) that challenges the recent decision by the United States Food and Drug Administration (FDA) to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI®. FDA granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (P
8-K - Liquidia Corp (0001819576) (Filer)
424B4 - Liquidia Corp (0001819576) (Filer)
8-K - Liquidia Corp (0001819576) (Filer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
SC 13G/A - Liquidia Corp (0001819576) (Subject)
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v
MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The
MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July 18, 2022. Roger Jeffs, Chief Executive Officer of Liquidia, said: "We are excited to add a leader of Dr. Saggar's caliber to our team as we prepare for the launch of YUTREPIA™ (treprostinil) inhalation powder upon receipt of final FDA approval. His expertise and credibility in treating patients across a wid
MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi
MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and ot
MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension
Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form
5 analysts have shared their evaluations of Liquidia (NASDAQ:LQDA) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $29.6, a high estimate of $32.00, and a low estimate of $28.00. No alteration is observed as the curre
Needham analyst Serge Belanger reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $28 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $32 price target.
Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy
Raymond James initiated coverage of Liquidia Technologies with a rating of Outperform and set a new price target of $27.00
Oppenheimer initiated coverage of Liquidia Technologies with a rating of Perform
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)